Toll Free: 1-888-928-9744

Silence Therapeutics plc - Product Pipeline Review - 2014

Published: Mar, 2014 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Silence Therapeutics plc - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Silence Therapeutics plc - Product Pipeline Review - 2014', provides an overview of the Silence Therapeutics plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Silence Therapeutics plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Silence Therapeutics plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Silence Therapeutics plc's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Silence Therapeutics plc's pipeline products

Reasons to buy

- Evaluate Silence Therapeutics plc's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Silence Therapeutics plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Silence Therapeutics plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Silence Therapeutics plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Silence Therapeutics plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Silence Therapeutics plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Silence Therapeutics plc Snapshot 5
Silence Therapeutics plc Overview 5
Key Information 5
Key Facts 5
Silence Therapeutics plc - Research and Development Overview 6
Key Therapeutic Areas 6
Silence Therapeutics plc - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Silence Therapeutics plc - Pipeline Products Glance 13
Silence Therapeutics plc - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Silence Therapeutics plc - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Silence Therapeutics plc - Drug Profiles 17
Atu-027 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Atu-111 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Atu-1112 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Atu-134 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Atu-150 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Atu-195 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
DACC Programs For Lung Diseases 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
DBTC Program for Liver Diseases 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Silence Therapeutics plc - Pipeline Analysis 26
Silence Therapeutics plc - Pipeline Products by Target 26
Silence Therapeutics plc - Pipeline Products by Route of Administration 27
Silence Therapeutics plc - Pipeline Products by Molecule Type 28
Silence Therapeutics plc - Pipeline Products by Mechanism of Action 29
Silence Therapeutics plc - Recent Pipeline Updates 30
Silence Therapeutics plc - Dormant Projects 34
Silence Therapeutics plc - Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37
List of Tables
Silence Therapeutics plc, Key Information 5
Silence Therapeutics plc, Key Facts 5
Silence Therapeutics plc - Pipeline by Indication, 2014 8
Silence Therapeutics plc - Pipeline by Stage of Development, 2014 9
Silence Therapeutics plc - Monotherapy Products in Pipeline, 2014 10
Silence Therapeutics plc - Partnered Products in Pipeline, 2014 11
Silence Therapeutics plc - Partnered Products/ Combination Treatment Modalities, 2014 12
Silence Therapeutics plc - Phase II, 2014 13
Silence Therapeutics plc - Phase I, 2014 14
Silence Therapeutics plc - Preclinical, 2014 15
Silence Therapeutics plc - Discovery, 2014 16
Silence Therapeutics plc - Pipeline by Target, 2014 26
Silence Therapeutics plc - Pipeline by Route of Administration, 2014 27
Silence Therapeutics plc - Pipeline by Molecule Type, 2014 28
Silence Therapeutics plc - Pipeline Products by Mechanism of Action, 2014 29
Silence Therapeutics plc - Recent Pipeline Updates, 2014 30
Silence Therapeutics plc - Dormant Developmental Projects,2014 34
Silence Therapeutics plc, Other Locations 35 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify